-
China Resources Biopharmaceutical Secures RMB 600 Million in Series B Funding
•
China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round, raising RMB 600 million (USD 88.5 million). The funding was led by China Structural Reform Fund, with contributions from China State-owned Enterprise Mixed Ownership Reform Fund, CCB PE, Technology Financial Group, and Guolian Group. The…
-
Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy
•
China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has announced data for its masked anti-CTLA-4 SAFEbody, ADG126, in combination with anti-PD-1 therapy in patients with advanced/metastatic solid tumors. The results, as of January 6, 2023, demonstrate the safety and initial efficacy profiles of ADG126…
-
Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms
•
Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare conference in San Francisco, denied that talks were being held with the Chinese government on potentially licensing Paxlovid (nirmatrelvir, ritonavir) to local generic firms in China. Bourla’s comments countered a report from Reuters that claimed…
-
Legend Biotech Receives Nasdaq Notice Regarding Listing Compliance
•
Legend Biotech Corporation (NASDAQ: LEGN) announced on January 6, 2023, that it received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating that the company is not currently in compliance with Nasdaq’s Listing Rules. The non-compliance is due to the company’s failure to file an…
-
Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study
•
China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its oral drug JMKX003142 in polycystic nephropathy. This marks a significant step forward in the development of a potential new treatment for this chronic kidney condition. Disease Background…
-
Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute
•
The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) notably absent despite widespread anticipation. The National Healthcare Security Administration (NHSA) cited a failure to agree on a price point as the reason for Paxlovid’s exclusion. Industry observers speculated that the NHSA…
-
China Strengthens COVID-19 Prevention and Control in Rural Areas
•
China has intensified its COVID-19 prevention and control measures in rural areas, with the State Council recently releasing two work plans aimed at improving medical care security and strengthening infection control. The plans, titled “Work Plan for Improving COVID-19 Medical Care Security Capacity in Rural Areas by Relying on County…
-
Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China
•
The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable donanemab is set to obtain the breakthrough therapy designation (BTD) status for use in early symptomatic Alzheimer’s disease (AD), including mild cognitive impairment caused by Alzheimer’s disease and mild Alzheimer’s disease. This marks a significant…
